DR. TERRENCE J BRADLEY MD
Prescription History 1134495021
Internal Medicine - Hematology in Miami, FL
Medicare Part D Prescription History
Explore the verified Medicare Part D prescription history, volume metrics, and calculated drug costs for DR. TERRENCE J BRADLEY MD, an active Hematology specialist practicing in Miami, FL. Our medical registry currently tracks 14 unique pharmaceutical formulations prescribed by this provider, representing an estimated volume of 233 documented patient claims. Among these therapy options, the most frequently utilized medication is Venclexta, which accounts for 40 claims alone. Use the table below to sort by claims, cost, or utilization compared with the state average; select any medication for its full profile.
| Medication | Prescriptions (2024)Rx (2024) | Avg Cost per FillCost / Fill | Vs. Other FL PrescribersVs. FL Avg |
|---|---|---|---|
| VenclextaVenetoclax | 40 | $3,669.76▼ below FL avg | ▲ More than typical |
About Venclexta: This medication is used to treat certain types of cancer (chronic lymphocytic leukemia-CLL, small lymphocytic lymphoma-SLL, acute myeloid leukemia-AML). Show more ▾ Venetoclax is a drug that works by helping to slow or stop the growth of cancer cells. A BCL-2 inhibitor with antineoplastic activity that is used in the treatment of CHRONIC LYMPHOCYTIC LEUKEMIA associated with chromosome 17p deletion. In 2024, this provider wrote 40 Medicare prescriptions for Venclexta, about 1.7 times the volume of the typical Florida prescriber of this medication (23). Medicare paid an average of $3,669.76 per fill, versus $8,623.50 statewide. How often this provider prescribes it This provider prescribes this medication more often than the average FL prescriber. Utilization reflects practice size as well as clinical preference. What Medicare paid per fill This provider's average cost per fill is below the FL average for this medication. 40 30-Day Fills standardized to 30-day supplies 1,106 Days of Medication total across all patients in 2024 | |||
| InqoviDecitabine/Cedazuridine | 28 | $7,918.52▼ below FL avg | ▲ More than typical |
About Inqovi: This medication contains 2 ingredients: decitabine and cedazuridine. Show more ▾ It is used to treat a group of blood/bone marrow disorders (myelodysplastic syndromes-MDS) in which the bone marrow does not produce enough healthy blood cells. People with MDS may have problems such as infections, anemia, and easy bleeding/bruising. Decitabine is thought to work by helping your bone marrow make normal blood cells. Decitabine also slows or stops the growth of abnormal blood cells that grow too fast and do not work properly. Cedazuridine helps decitabine work better by helping to prevent its breakdown in your body. In 2024, this provider wrote 28 Medicare prescriptions for Inqovi, about 1.5 times the volume of the typical Florida prescriber of this medication (19.2). Medicare paid an average of $7,918.52 per fill, versus $8,112.63 statewide. How often this provider prescribes it This provider prescribes this medication more often than the average FL prescriber. Utilization reflects practice size as well as clinical preference. What Medicare paid per fill This provider's average cost per fill is below the FL average for this medication. 28 30-Day Fills standardized to 30-day supplies 784 Days of Medication total across all patients in 2024 | |||
| Hydroxyurea | 20 | $20.20▼ below FL avg | ▼ Less than typical |
About Hydroxyurea: This medication is used by people with sickle cell anemia to reduce the number of painful crises caused by the disease and to reduce the need for blood transfusions. Show more ▾ Some brands are also used to treat certain types of cancer (such as chronic myelogenous leukemia, squamous cell carcinomas). An antineoplastic agent that inhibits DNA synthesis through the inhibition of ribonucleoside diphosphate reductase. In 2024, this provider wrote 20 Medicare prescriptions for Hydroxyurea, about half the volume of the typical Florida prescriber of this medication (33.8). Medicare paid an average of $20.20 per fill, versus $25.55 statewide. How often this provider prescribes it This provider prescribes this medication less often than the average FL prescriber. Utilization reflects practice size as well as clinical preference. What Medicare paid per fill This provider's average cost per fill is below the FL average for this medication. 38 30-Day Fills standardized to 30-day supplies 1,125 Days of Medication total across all patients in 2024 | |||
| JakafiRuxolitinib Phosphate | 20 | $13,688.30▼ below FL avg | ≈ Typical |
About Jakafi: This medication is used to treat certain bone marrow disorders (myelofibrosis, polycythemia vera). Show more ▾ It works by blocking your body from producing substances called growth factors. Growth factors cause cells to grow and divide, and cause the blood cell and spleen problems found in these disorders. Ruxolitinib belongs to a class of drugs known as kinase inhibitors. Though not a cure for these disorders, ruxolitinib may help with some of the symptoms, including abdominal discomfort, pain under left ribs, early feelings of fullness from meals, night sweats, itching, and bone/muscle pain. Ruxolitinib is also used to treat a certain problem that may occur after certain stem cell or bone marrow transplants (graft versus host disease). It works by weakening your body's defense system (immune system). In 2024, this provider wrote 20 Medicare prescriptions for Jakafi, about 78% of the volume of the typical Florida prescriber of this medication (25.8). Medicare paid an average of $13,688.30 per fill, versus $16,440.88 statewide. How often this provider prescribes it This provider's prescribing volume for this medication is in line with the average FL prescriber. Utilization reflects practice size as well as clinical preference. What Medicare paid per fill This provider's average cost per fill is below the FL average for this medication. 20 30-Day Fills standardized to 30-day supplies 600 Days of Medication total across all patients in 2024 | |||
| Acyclovir | 15 | $13.79▼ below FL avg | ▼ Less than typical |
About Acyclovir: Acyclovir is used to treat infections caused by certain types of viruses. Show more ▾ It treats cold sores around the mouth (caused by herpes simplex), shingles (caused by herpes zoster), and chickenpox. This medication is also used to treat outbreaks of genital herpes. In people with frequent outbreaks, acyclovir is used to help reduce the number of future episodes. Acyclovir is an antiviral drug. However, it is not a cure for these infections. The viruses that cause these infections continue to live in the body even between outbreaks. Acyclovir decreases the severity and length of these outbreaks. It helps the sores heal faster, keeps new sores from forming, and decreases pain/itching. This medication may also help reduce how long pain remains after the sores heal. In addition, in people with a weakened immune system, acyclovir can decrease the risk of the virus spreading to other parts of the body and causing serious infections. A GUANOSINE analog that acts as an antimetabolite. Viruses are especially susceptible. Used especially against herpes. In 2024, this provider wrote 15 Medicare prescriptions for Acyclovir, about 61% of the volume of the typical Florida prescriber of this medication (24.6). Medicare paid an average of $13.79 per fill, versus $21.26 statewide. How often this provider prescribes it This provider prescribes this medication less often than the average FL prescriber. Utilization reflects practice size as well as clinical preference. What Medicare paid per fill This provider's average cost per fill is below the FL average for this medication. 25 30-Day Fills standardized to 30-day supplies 750 Days of Medication total across all patients in 2024 | |||
| Ondansetron Hcl | 14 | $8.41▼ below FL avg | ▼ Less than typical |
About Ondansetron Hcl: This medication is used alone or with other medications to prevent nausea and vomiting caused by cancer drug treatment (chemotherapy) and radiation therapy. Show more ▾ It is also used to prevent and treat nausea and vomiting after surgery. It works by blocking one of the body's natural substances (serotonin) that causes vomiting. A competitive serotonin type 3 receptor antagonist. It is effective in the treatment of nausea and vomiting caused by cytotoxic chemotherapy drugs, including cisplatin, and has reported anxiolytic and neuroleptic properties. In 2024, this provider wrote 14 Medicare prescriptions for Ondansetron Hcl, about half the volume of the typical Florida prescriber of this medication (29.9). Medicare paid an average of $8.41 per fill, versus $26.98 statewide. How often this provider prescribes it This provider prescribes this medication less often than the average FL prescriber. Utilization reflects practice size as well as clinical preference. What Medicare paid per fill This provider's average cost per fill is below the FL average for this medication. 14 30-Day Fills standardized to 30-day supplies 210 Days of Medication total across all patients in 2024 | |||
| IdhifaEnasidenib Mesylate | 13 | $34,388.35▼ below FL avg | ≈ Typical |
About Idhifa: This medication is used to treat a certain type of blood cell cancer (acute myeloid leukemia-AML). Show more ▾ Enasidenib works by helping your bone marrow grow normal blood cells so you will need fewer blood transfusions. This drug has been withdrawn from the Canadian market due to problems with effectiveness. An inhibitor of isocitrate dehydrogenase 2 (IDH2). In 2024, this provider wrote 13 Medicare prescriptions for Idhifa, about 82% of the volume of the typical Florida prescriber of this medication (15.8). Medicare paid an average of $34,388.35 per fill, versus $35,354.42 statewide. How often this provider prescribes it This provider's prescribing volume for this medication is in line with the average FL prescriber. Utilization reflects practice size as well as clinical preference. What Medicare paid per fill This provider's average cost per fill is below the FL average for this medication. 13 30-Day Fills standardized to 30-day supplies 390 Days of Medication total across all patients in 2024 | |||
| InrebicFedratinib Dihydrochloride | 13 | $24,348.76 | ≈ Typical |
About Inrebic: This medication is used to treat a certain type of cancer (myelofibrosis). Show more ▾ Fedratinib belongs to a class of drugs known as kinase inhibitors. It works by slowing or stopping the growth of cancer cells. A selective small-molecule inhibitor of JAK2. In 2024, this provider wrote 13 Medicare prescriptions for Inrebic, about the same volume as the typical Florida prescriber of this medication (12.3). Medicare paid an average of $24,348.76 per fill, versus $18,515.29 statewide. How often this provider prescribes it This provider's prescribing volume for this medication is in line with the average FL prescriber. Utilization reflects practice size as well as clinical preference. What Medicare paid per fill Gross Part D cost per fill; not the patient's out-of-pocket price. 13 30-Day Fills standardized to 30-day supplies 360 Days of Medication total across all patients in 2024 | |||
| OjjaaraMomelotinib Dihydrochloride | 13 | $27,832.13 | ▼ Less than typical |
About Ojjaara: This medication is used to treat a certain type of cancer (myelofibrosis) in people with anemia (low red blood cell count). Show more ▾ Momelotinib belongs to a class of drugs known as kinase inhibitors. It works by blocking your body from producing substances called growth factors. Growth factors cause cells to grow and divide, and cause the blood cell and spleen problems found in myelofibrosis. Though not a cure for this condition, momelotinib may help with some of the symptoms, including abdominal discomfort, pain under left ribs, early feelings of fullness from meals, night sweats, itching, and bone/muscle pain. A Janus kinase 1 and Janus kinase 2 inhibitor. In 2024, this provider wrote 13 Medicare prescriptions for Ojjaara, about 67% of the volume of the typical Florida prescriber of this medication (19.4). Medicare paid an average of $27,832.13 per fill, versus $27,748.59 statewide. How often this provider prescribes it This provider prescribes this medication less often than the average FL prescriber. Utilization reflects practice size as well as clinical preference. What Medicare paid per fill Gross Part D cost per fill; not the patient's out-of-pocket price. 13 30-Day Fills standardized to 30-day supplies 390 Days of Medication total across all patients in 2024 | |||
| VonjoPacritinib Citrate | 12 | $24,434.74 | ≈ Typical |
About Vonjo: This medication is used to treat a certain bone marrow disorder (myelofibrosis). Show more ▾ It works by blocking your body from producing substances called growth factors. Pacritinib belongs to a class of drugs known as kinase inhibitors. For treating lymphoma and myelofibrosis. In 2024, this provider wrote 12 Medicare prescriptions for Vonjo, about 86% of the volume of the typical Florida prescriber of this medication (13.9). Medicare paid an average of $24,434.74 per fill, versus $22,927.85 statewide. How often this provider prescribes it This provider's prescribing volume for this medication is in line with the average FL prescriber. Utilization reflects practice size as well as clinical preference. What Medicare paid per fill Gross Part D cost per fill; not the patient's out-of-pocket price. 12 30-Day Fills standardized to 30-day supplies 360 Days of Medication total across all patients in 2024 | |||
| XareltoRivaroxaban | 12 | $523.58▼ below FL avg | ▼ Less than typical |
About Xarelto: Rivaroxaban is used to prevent blood clots from forming due to a certain irregular heartbeat (atrial fibrillation) or after hip or knee replacement surgery. Show more ▾ It is also used to prevent blood clots from forming in high-risk patients with limited mobility during their hospital stay and after discharge. In addition, rivaroxaban is used to treat blood clots (such as in deep vein thrombosis-DVT or pulmonary embolus-PE) and to prevent the blood clots from forming again. Rivaroxaban may be used in children to prevent blood clots from forming after a certain heart surgery (Fontan procedure). Rivaroxaban is an anticoagulant that works by blocking certain clotting proteins in your blood. A morpholine and thiophene derivative that functions as a FACTOR XA INHIBITOR and is used in the treatment and prevention of DEEP-VEIN THROMBOSIS and PULMONARY EMBOLISM. It is also used for the prevention of STROKE and systemic embolization in patients with non-valvular ATRIAL FIBRILLATION, and for the prevention of atherothrombotic events in patients after an ACUTE CORONARY SYNDROME. In 2024, this provider wrote 12 Medicare prescriptions for Xarelto, about a quarter of the volume of the typical Florida prescriber of this medication (44.6). Medicare paid an average of $523.58 per fill, versus $951.72 statewide. How often this provider prescribes it This provider prescribes this medication less often than the average FL prescriber. Utilization reflects practice size as well as clinical preference. What Medicare paid per fill This provider's average cost per fill is below the FL average for this medication. 12 30-Day Fills standardized to 30-day supplies 360 Days of Medication total across all patients in 2024 | |||
| Doxazosin Mesylate | 11 | $7.65▼ below FL avg | ▼ Less than typical |
About Doxazosin Mesylate: Doxazosin is used alone or with other drugs to treat high blood pressure (hypertension). Show more ▾ Lowering high blood pressure helps prevent strokes, heart attacks, and kidney problems. This medication works by relaxing blood vessels so blood can flow more easily. Doxazosin is also used in men to treat the symptoms of an enlarged prostate (benign prostatic hyperplasia-BPH). It does not shrink the prostate, but it works by relaxing the muscles in the prostate and part of the bladder. This helps to relieve symptoms of BPH such as difficulty in beginning the flow of urine, weak stream, and the need to urinate often or urgently (including during the middle of the night). Doxazosin belongs to a class of drugs known as alpha blockers. A prazosin-related compound that is a selective alpha-1-adrenergic blocker. In 2024, this provider wrote 11 Medicare prescriptions for Doxazosin Mesylate, about a third of the volume of the typical Florida prescriber of this medication (27.9). Medicare paid an average of $7.65 per fill, versus $17.00 statewide. How often this provider prescribes it This provider prescribes this medication less often than the average FL prescriber. Utilization reflects practice size as well as clinical preference. What Medicare paid per fill This provider's average cost per fill is below the FL average for this medication. 13 30-Day Fills standardized to 30-day supplies 390 Days of Medication total across all patients in 2024 | |||
| Imipenem-Cilastatin SodiumImipenem/Cilastatin Sodium | 11 | $630.73 | ▼ Less than typical |
About Imipenem-Cilastatin Sodium: This medication is used to treat a wide variety of bacterial infections. Show more ▾ This medication is known as a carbapenem-type antibiotic. It works by stopping the growth of bacteria. Combination of imipenem and cilastatin that is used in the treatment of bacterial infections; cilastatin inhibits renal dehydropeptidase I to prolong the half-life and increase the tissue penetration of imipenem, enhancing its efficacy as an anti-bacterial agent. In 2024, this provider wrote 11 Medicare prescriptions for Imipenem-Cilastatin Sodium, about 60% of the volume of the typical Florida prescriber of this medication (18.2). Medicare paid an average of $630.73 per fill, versus $461.68 statewide. How often this provider prescribes it This provider prescribes this medication less often than the average FL prescriber. Utilization reflects practice size as well as clinical preference. What Medicare paid per fill Gross Part D cost per fill; not the patient's out-of-pocket price. 11 30-Day Fills standardized to 30-day supplies 71 Days of Medication total across all patients in 2024 | |||
| ScemblixAsciminib Hydrochloride | 11 | $21,530.91▼ below FL avg | ≈ Typical |
About Scemblix: Asciminib is used to treat a certain type of cancer (chronic myeloid leukemia-CML). Show more ▾ Asciminib belongs to a class of drugs known as kinase inhibitors. It works by slowing or stopping the growth of cancer cells. Inhibits ABL1 protein. In 2024, this provider wrote 11 Medicare prescriptions for Scemblix, about 79% of the volume of the typical Florida prescriber of this medication (13.9). Medicare paid an average of $21,530.91 per fill, versus $23,429.48 statewide. How often this provider prescribes it This provider's prescribing volume for this medication is in line with the average FL prescriber. Utilization reflects practice size as well as clinical preference. What Medicare paid per fill This provider's average cost per fill is below the FL average for this medication. 11 30-Day Fills standardized to 30-day supplies 330 Days of Medication total across all patients in 2024 | |||
About this data. The prescription history for DR. TERRENCE J BRADLEY MD is compiled from the Centers for Medicare & Medicaid Services (CMS) Medicare Part D Prescriber Public Use File for calendar year 2024, the most recent federal release. Figures cover prescriptions filled for Medicare Part D beneficiaries only; prescriptions under private insurance, Medicaid, or self-pay plans are not included. Because prescribing decisions are generally consistent across coverage types, this record offers a useful view of the overall Hematology prescribing approach at this Miami, FL practice.
Reading the costs. Drug costs are gross amounts paid to pharmacies under Part D, including both plan and beneficiary payments. They are not the price a patient pays at the pharmacy counter. Medications with fewer than 11 claims are excluded from the federal source data, and state comparisons use the average among FL prescribers of the same medication and form, shown only when at least five prescribers contribute. Always confirm current medications and costs directly with the provider and your plan.
About the medication summaries. Drug use descriptions come from the CMS Medicare Part D Drug Spending Dashboard (2024), and substance definitions from Medical Subject Headings (MeSH) 2026, U.S. National Library of Medicine. They are summaries that do not contain all possible information about a medication and are not individual medical advice. Ask a health care professional about any medication and your specific health needs.
